All In Biotech

Drug Trial Radar · NCT00476996

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy

Last checked: Nov 20, 2026Latest source record: Aug 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 836 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

836

Actual

Start

May 15, 2007

Primary completion

Jan 21, 2010

Study completion May 14, 2018

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Roche Pharma AG
First posted
May 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26. All patients will receive stable doses of either concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive additional DMARDs. The treatment period is planned for 48 weeks (until primary analysis) and then participants will enter the open label phase until the drug is commercialized. Target sample size is 1000.

Conditions

  • Rheumatoid Arthritis

Interventions

  • LeflunomideDrug

    Oral repeating dose

  • MethotrexateDrug

    Oral or parenteral repeating dose

  • OcrelizumabDrug

    Intravenous repeating dose (200mg)

  • OcrelizumabDrug

    Intravenous repeating dose (500mg)

  • PlaceboDrug

    Intravenous repeating dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With American College of Rheumatology 20 (ACR20) ResponsesTime frame: Weeks 24 and 48

Locations

266 sites in 25 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group; Llc, Central

    Anniston, Alabama

  • Rheumatology Associates

    Birmingham, Alabama

  • Rheumatology Associates of North Alabama

    Huntsville, Alabama

  • Arizona Arthritis & Rheumatology Research, Pllc

    Mesa, Arizona

  • Arthrocare, Arthritis Care and Research, P.C.

    Mesa, Arizona

  • Catalina Pointe Clinical Research, Inc.

    Tucson, Arizona

  • Uni of Arizona Health Science Center; Dept of Rheumatology/Immunology

    Tucson, Arizona

  • CHI St. Vincent Medical Group Hot Springs

    Hot Springs, Arkansas

  • Little Rock Diagnostic Clinic

    Little Rock, Arkansas

  • Allergy & Rheumatology Centre

    La Jolla, California

  • Private Practice

    Long Beach, California

  • Valerius Medical Group & Research Ctr of Greater Long Beach

    Los Alamitos, California

  • Uni of Southern California School of Medicine

    Los Angeles, California

  • Pacific Arthritis Care Center

    Los Angeles, California

  • Stanford Uni Medical Center; Divison of Rheumatology

    Palo Alto, California

  • Ucsd, Dept of Medicine; Rheumatology

    San Diego, California

  • San Diego Arthritis Med Clnc

    San Diego, California

  • East Bay Rheumatology

    San Leandro, California

  • Arthritis Treatment Center of South Bay

    Torrance, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs

    Colorado Springs, Colorado

  • Arthritis & Osteoporosis Center P.C.

    Camden, Connecticut

  • New England Research Associates

    Trumbull, Connecticut

  • Rheumatolgy Consultants of Deleware

    Lewes, Delaware

  • Javed Rheumatology Associates, Inc.

    Newark, Delaware

  • Arthritis & Rheumatism; Disease Specialities

    Aventura, Florida

  • Jacksonville Center For Clinical Research

    Jacksonville, Florida

  • Arthritis Center Palm Harbor

    Palm Harbor, Florida

  • Arthritis Rsrch of Florida, Inc.

    Palm Harbor, Florida

  • Sarasota Arthritis Center; Research Dept

    Sarasota, Florida

  • Center For Arthritis; Research Dept

    South Miami, Florida

  • SW Florida Clinical Research

    Tampa, Florida

  • Tampa General Hospital; Rheumatology Research Dept

    Tampa, Florida

  • Burnette & Silverfield, MDS

    Tampa, Florida

  • Florida Medical Center

    Zephyrhills, Florida

  • Atlanta Center For Clinical Research.

    Atlanta, Georgia

  • Csi Research, Inc.

    Cumming, Georgia

  • Marietta Rheumatology Associates, Pc

    Marietta, Georgia

  • Intermountain Orthopaedics

    Boise, Idaho

  • Coeur D'Alene Arthritis Clinic

    Coeur d'Alene, Idaho

Showing 40 of 266 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.